Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

More documents

Recommendations

Info

Avastin in 1st line mCRC: the only biologic with significant survival benefit Study Regimen OS Study arm Crystal Folfiri +/- Cetuximab OS control Benefit (detriment) ITT 19.9 18.6 1.3 0.93 0.30 K-Ras WT 24.9 21.0 3.9 0.84 0.22 AVF 2107 IFL+/-Avastin ITT 20.3 15.6 4.7 0.66
Avastin and cetuximab in combination with oxaliplatin-based regimen Study Regimen PFS Study arm Opus Folfox +/- Cetuximab PFS control Benefit (detriment) ITT 7.2 7.2 0 0.93 0.62 K-RAS WT 7.7 7.2 0.5 0.57 0.016 K-Ras mut 5.5 8.6 -3.1 1.83 0.019 Cairo 2 Xelox-Avastin +/- Cetuximab ITT 9.6 10.7 -1.1 1.21 0.018 K-Ras WT 10.1 10.7 -0.6 na 0.1 K-Ras mut 8.6 12.5 -3.9 na 0.043 HR p 17
Page 1 and 2: Clinical Development at Roche: Driv
Page 3 and 4: Our new R&D model: Paradigm changes
Page 5 and 6: Biomarkers A central element throug
Page 7 and 8: Our new R&D model: Paradigm changes
Page 9 and 10: Enhance innovation …by maintainin
Page 11 and 12: Roche Pharma pipeline overview Focu
Page 13 and 14: Major Roche-managed oncology submis
Page 15: Avastin and cetuximab in combinatio
Page 19 and 20: Attacking the HER2 pathway from mul
Page 21 and 22: Implementing biomarker strategy for
Page 23 and 24: Key drivers for long term developme
Page 25 and 26: Actemra: The first IL-6 receptor in
Page 27 and 28: CETP Inhibitor R1658 is a unique CE
Page 29 and 30: Taspoglutide: investigational once-
Page 31 and 32: CD20 targeting: new treatment strat
Page 33 and 34: Roche R&D opportunities in summary
Page 35 and 36: Avastin’s position as standard of

Jean-Jacques Garaud, MD Global Head Pharma ... - Roche

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?